Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. TERMINATION AGREEMENTTermination Agreement • November 6th, 2020 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This TERMINATION AGREEMENT (this “Agreement”) is entered into on August 5, 2020 (the “Effective Date”) by and between Editas Medicine, Inc., a Delaware corporation (“Editas”), and Allergan Sales, LLC, a Delaware limited liability company (“Allergan”). Allergan and Editas are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
